KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Sales (2016 - 2025)

Acadia Pharmaceuticals has reported Return on Sales over the past 16 years, most recently at 0.08% for Q4 2025.

  • Quarterly results put Return on Sales at 0.08% for Q4 2025, down 47.0% from a year ago — trailing twelve months through Dec 2025 was 0.13% (down 11.0% YoY), and the annual figure for FY2025 was 0.13%, down 11.0%.
  • Return on Sales for Q4 2025 was 0.08% at Acadia Pharmaceuticals, down from 0.26% in the prior quarter.
  • Over the last five years, Return on Sales for ACAD hit a ceiling of 0.55% in Q4 2024 and a floor of 0.98% in Q1 2022.
  • Median Return on Sales over the past 5 years was 0.05% (2023), compared with a mean of 0.11%.
  • Biggest five-year swings in Return on Sales: soared 62bps in 2023 and later tumbled -47bps in 2025.
  • Acadia Pharmaceuticals' Return on Sales stood at 0.33% in 2021, then rose by 7bps to 0.31% in 2022, then surged by 165bps to 0.2% in 2023, then soared by 180bps to 0.55% in 2024, then crashed by -85bps to 0.08% in 2025.
  • The last three reported values for Return on Sales were 0.08% (Q4 2025), 0.26% (Q3 2025), and 0.1% (Q2 2025) per Business Quant data.